Evotec and The Leukemia & Lymphoma Society enter into a strategic research collaboration


Hamburg, Germany - 05 November 2013: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that it has entered into an integrated research collaboration with The Leukemia & Lymphoma Society ('LLS'). Evotec will support one of LLS's Screen-to-Lead Programs ('SLP'). In this collaboration, Evotec partners with LLS to support selected programmes and principal investigators with resources for high-throughput screening and optimisation of small molecules into drug-like compounds. Evotec delivers an industrialised, cutting-edge, comprehensive and unbiased drug discovery infrastructure to support innovation efficiency as part of a fully integrated solution.

Dr Mario Polywka, Chief Operating Officer of Evotec, commented: 'We are excited to initiate this collaboration and support The Leukemia and Lymphoma Society and their investigators. We are confident that our experienced scientists and innovation platform can deliver results for LLS, their investigators and ultimately patients.'

Amy Burd, Ph.D., Executive Director of Research at LLS, added: 'LLS is pleased to be working in collaboration with Evotec to advance our Screen-to-Lead programs. We feel that Evotec has the necessary skills and capabilities to offer significant value to support these projects.'

No financial details were disclosed. 


The Leukemia & Lymphoma Society (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, multiple myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care.
Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org. Patients should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.


 Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this report. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.